TABLE 1:
Patient, treatment, and follow-up data
| Patient No./Initials/Age (y)/Sex | Localization | Signs and Symptoms | Aneurysm (mm)* |
Onyx HD 500 (+) ml | Aneurysm Occlusion (%) | FU (mo) | DSA/MRA | Aneurysm Occlusion FU (%) | Signs and Symptoms FU | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Height | Width | Neck | |||||||||
| 1/NN/31/F | Ophth | Asymptomatic | 10 | 15 | 8 | 0.43 | 100 | 22 | DSA | 100 | Asymptomatic |
| 2/GH/41/F | Ophth (GDC) | Asymptomatic | 8 (15) | 10 | 6 | 0.3 | 95 | 12/36 | DSA/MRA | 100 | Asymptomatic |
| 3/KG/41/F | Ophth | Asymptomatic | 15 | 7.5 | 6 | 0.6 | 100 | —† | — | — | — |
| 4/MG/61/M | Clinoidal | Asymptomatic | 20 | 12 | 8 | 1.36 | 100 | 12/25 | DSA/DSA | 100 | Asymptomatic |
| 5/WU/39/F | Ophth | Asymptomatic | 25 | 25 | 12 | 2.5 | 100 | 12 | DSA | 100 | Asymptomatic |
| 6/CM/29/F | Ophth | Asymptomatic | 18 | 18 | 7 | 1.3 | 100 | 6/14 | MRA/MRA | 100 | Asymptomatic |
| 7/KJ/41/F | Ophth | Asymptomatic | 12 | 8 | 6 | 0.27 | 95 | 10 | DSA | 100 | TIA |
| 8/OH/65/F | Cav (GDC) | Cnp III | 20 (30) | 20 (25) | 12 | 4.68 | 100 | 5/18 | DSA/DSA | 100 | Cnp improved |
| 9/THJ/54/M | Ophth | Asymptomatic | 6 | 10 | 7 | 0.16 | 100 | 8 | DSA | 100 | Asymptomatic |
| 10/HB/35/F | Ophth | Asymptomatic | 6 | 12 | 8 | 0.32 (+) | 100 | 2/13 | MRA/DSA | 100 | Asymptomatic |
| 11/LK/52/F | Cav | Cnp III, IV | 25 | 36 | 18 | 2.43 (+) | 90 | 7 | DSA | 90‡ | Cnp improved |
| 12/SMT/47/F | Ophth | Asymptomatic | 10 | 8 | 6 | 0.36 (+) | 95 | 5 | DSA | 100 | Asymptomatic |
| 13/DJ/61/F | Cav | Cnp VI | 25 | 20 | 12 | 2.28 (+) | 100 | 4/16 | MRA/DSA | 85‡ | Unchanged |
| 14/KM/60/F | Ophth | Asymptomatic | 15 | 20 | 8 | 0.51 (+) | 100 | 5 | DSA | 100 | Asymptomatic |
| 15/BE/58/F | Ophth (GDC) | Asymptomatic | 15 (25) | 7 (12) | 6 | 0.42 (+) | 100 | 6 | DSA | 100 | Asymptomatic |
| 16/WA/35/F | Ophth (GDC) | Asymptomatic | 10 (25) | 17 | 8 | 0.73 (+) | 100 | 6 | MRA | 100 | Asymptomatic |
| 17/WG/50/F | Cav | Cnp II | 18 | 20 | 16 | 0.79 (+) | 100 | Pending | Pending | Pending | Pending |
| 18/BI/60/F | Cav | Asymptomatic | 23 | 15 | 8 | 1.90 (+) | 100 | 6 wk | DSA | 100 | Asymptomatic |
| 19/KR/45/F | Ophth (GDC) | Asymptomatic | 25 | 12 | 6 | 0.42 (+) | 100 | 12/30 | DSA/MRA | 100 | Asymptomatic |
| 20/LG/59/F | Cav | Cnp IV | 20 | 15 | 10 | 2.15 (+) | 100 | 7 | DSA | 100 | Asymptomatic |
| 21/WA/61/F | Ophth (GDC) | Cnp II | 18 (30) | 13 (25) | 10 | 1.55 (+) | 100 | 8 | DSA | 100 | Unchanged |
| 22/ML/42/F | Ophth (GDC) | Asymptomatic | 10 (20) | 7 (12) | 8 | 0.41 (+) | 100 | 8 | DSA | 100 | Asymptomatic |
Note.—(+) indicates Onyx HD+ with increased visibility; Ophth = ophthalmic segment of the carotid artery; Cav, cavernous segment of the carotid artery; GDC, recurrent aneurysm after treatment with Guglielmi detachable coils; FU, follow-up; TIA, transient ischemic attack; Cnp, cranial nerve paresis; DSA, digital subtraction angiography; mRA, magnetic resonance angiography.
*
Dimensions of the contrasted lumen of the aneurysms are followed in parentheses by dimensions of the complete aneurysms before treatment.
†
Occlusion of the internal carotid artery after vessel rupture due to balloon inflation during the procedure.
‡
Recurrence after Onyx treatment, occluded with coils and self-expandable stents.